Investor Ideas #Potcasts 524, #Cannabis News and #Stocks on the Move; (TSX: $TGOD.TO) (OTC: $TGODF) (NASDAQ: $NEPT) (TSX: $NEPT.TO) (NYSE: $ACB) (TSX: $ACB.TO)
Delta, Kelowna, BC, January 29, 2020 (Investorideas.com Newswire) www.Investorideas.com, a global news source covering leading sectors including marijuana and hemp stocks and its potcast site, www.potcasts.ca release today’s podcast edition of cannabis news and stocks to watch plus insight from thought leaders and experts.
Listen to the podcast:
Read this in full at https://www.investorideas.com/news/2021/cannabis-potcasts/01291TGOD-NEPT-ACB.asp
Today’s podcast overview/transcript:
Good afternoon and welcome to another episode of Investorideas.com "Potcast" featuring cannabis news, stocks to watch as well as insights from thought leaders and experts.
In today’s podcast we will be looking at a few public and private company announcements.
The Green Organic Dutchman Holdings Ltd. (TSX: TGOD) (OTC: TGODF), a leading producer of premium certified organically grown cannabis, announced the launch of RIPPLE Gummies by TGOD, Canada's first cannabis-infused confectionary product to offer a scientifically validated 15-minute onset. They will initially be available in Alberta, British Columbia, and Manitoba, with plans to expand distribution across the country once provincial listings are received.
RIPPLE Gummies are made using certified organically grown cannabis, real fruit juice and all-natural flavours and colours. Each pack contains two precisely dosed 5mg THC-gummies for a total of 10mg, the maximum allowed under Canada's Cannabis Act.
RIPPLE Gummies leverage the same fast-acting proprietary technology used in quick-dissolving RIPPLE powder, which rapidly became one of the top-selling SKUs within the cannabis beverage category due to its scientifically validated 15-minute onset, a first in Canada.
"Canadian cannabis consumers love our quick-dissolving RIPPLE powder for its proven dose-controlled delivery mechanism; it offers a faster-acting, more standardized, and discreet alternative to most products currently on the market. With RIPPLE Gummies, we are bringing to market another proven product which has been a top seller where sold in the United States," commented Sean Bovingdon, TGOD's Chief Financial Officer and Interim Chief Executive Officer. "RIPPLE Gummies offer another convenient option for Canadians to consume their desired dose of cannabinoids with a unique, predictable onset of action."
As part of its licensing agreement with Stillwater, TGOD plans to further expand its RIPPLE offering with additional flavours Honey Infusion CBD and Mango Balance, scheduled to launch in the second quarter of 2021.
Gage Growth Corp., the leading high-quality craft cannabis brand in Michigan, has announced the final closing of its Regulation A, Tier 2, equity financing. In total, Gage issued 28,571,400 Subordinate Voting Shares for gross proceeds of US$50,000,000, the maximum amount qualified under the Company's offering circular (see Gage Cannabis Co. Offering Circular). The oversubscribed Offering included demand from both institutional and retail investors and significantly expanded the Company's ownership base through the addition of over 1,000 new shareholders.
The Company expects to use the proceeds from the Offering to expand its retail footprint, pursue accretive acquisitions, and help position and solidify Gage as the leading cannabis brand in the state of Michigan.
"We are humbled and excited by the significant interest and investor demand we received for our oversubscribed Reg A financing," said Fabian Monaco, President of Gage. "Michigan is one of the fastest growing cannabis markets in the United States, and Gage is well positioned with a robust balance sheet to continue to grow our market share as the leading operator with the best brands in the state. This is a great first step in our journey to becoming a publicly-traded company, and we're excited to continue to drive long-term shareholder value."
As previously announced, the Company continues to pursue a potential go-public transaction which it expects to complete in Q1 2021. Please do not hesitate to contact their Investor Relations team for further information or to be added to our shareholder distribution list at IR@GageUSA.com.
Gage Growth Corp. is innovating and curating the highest quality cannabis experiences possible for cannabis consumers in the state of Michigan and bringing internationally renowned brands to market. Through years of progressive industry experience, the firm's founding partners have successfully built and grown operations with federal and state licenses, including cultivation, processing and retail locations. Gage's portfolio includes city and state approvals for "Class C" cultivation licenses, processing licenses and provisioning centers (dispensaries). To learn more, please visit www.GageUSA.com.
Longtime industry partners and cannabis research leaders, The Arcview Group and National Cannabis Industry Association (NCIA), champion equity, advocate for social justice, and help those affected by the war on drugs. Together, the two groups are honoring the inauguration of the first female Vice President of the United States through a series of whitepapers conceptualized by Andrew Kline, the former Public Policy Director of NCIA, and written by a collection of exceptional women.
"The new presidential administration's pro-cannabis stance is already making waves in our industry and creating excitement around navigating new challenges over the next four years," comments Laura Toomey, Chief of Staff of The Arcview Group. "As more opportunities in cannabis arise across the country, Arcview's newly renamed Women's Inclusion Network is concurrently on a mission to bring more females to the forefront of the industry through the creation of empowering educational materials developed by women for women."
Seeking positive change towards gender equality, Gail Rand, CEO and Founder of grand consulting, and Jessica Billingsly, CEO and Chairman of the Board of Akerna, co-led authorship of a series of whitepapers titled "Building New Foundations in the Cannabis Industry: Creating Gender Parity through Ownership, Leadership, Boards, Pay Equality, Branding, and Capital."
"The papers cover a variety of timely topics and are focused on identifying problems commonly faced by women executives. Our hope is that people will use these as a resource to help them succeed and positively impact the future of the cannabis industry," states Gail Rand.
The five papers authored by notable industry leaders include:
- Gender Parity in the C-Suite by Christine De La Rosa of The People's Dispensary, Kelly Perez of kindColorado, and Elise Serbaroli of Strimo.
- Pristine Companies Aren't Good Enough for Cannabis Capital by Debra Borchardt of Green Market Report and Gaynell Rogers of Treehouse Global Ventures.
- Product Development and Branding by Nancy Whiteman of Wana, BDSA Market Research, and Alison Pugina of Canopy Growth Corporation.
- Pathways to Equity Ownership by Elise Serbaroli of Strimo, Christine De La Rosa of The People's Dispensary, and Debra Borchardt of Green Market Report.
- Pay Equity: Minding the "Gap" by Risa Lavine of CohnReznick.
Whitepapers, key research takeaways, success toolkits, and the paper's foreword written by Jeanne M. Sullivan, Chief Investment Officer of Arcview Ventures and Founder of Women's Inclusion Network, will be rolled out for free download starting Thursday, Jan. 28, 2021.
"The document is well-prepared by successful women that represent the perspectives of all women whether Black, Brown, or White and in different verticals within the cannabis industry. The papers will inspire women with advice about successful entry and sustainability within the industry. Every woman seeking to enter the cannabis industry will benefit from reading it and attending the virtual event," said Khadijah Adams, Chair of NCIA's Diversity, Equity & Inclusion Committee.
To jumpstart gender balance in the cannabis industry, The Arcview Group and NCIA invite business owners to join them for an educational webinar led by whitepaper authors on February 5, 2021, at 11:00 a.m. PT/2:00 p.m. ET. Registration is free and includes a fireside chat with Kim Kovacs, CEO of The Arcview Group, and Jeanne M. Sullivan, Chief Investment Officer of Arcview Ventures. All registrants will also gain access to five exclusive virtual after-parties that take a deep dive into each paper.
Register for the webinar, get access to download all five whitepapers, and learn more about each author at www.ArcviewGroup.com/NCIA.
Aurora Cannabis Inc. (NYSE: ACB) (TSX: ACB), the Canadian company defining the future of cannabinoids worldwide, announced today that it has scheduled a conference call on Thursday, February 11, 2021 at 5:00 p.m. Eastern Time to discuss the results for its fiscal year 2021 second quarter ended December 31, 2020. Miguel Martin, Chief Executive Officer, and Glen Ibbott, Chief Financial Officer, will host the call and a question and answer period. The Company will report its financial results for the fiscal second quarter after the close of markets on Thursday, February 11, 2021.
Neptune Wellness Solutions, Inc. (NASDAQ: NEPT) (TSX: NEPT), a diversified and fully integrated health and wellness company focused on natural, plant-based, sustainable and purpose-driven lifestyle brands, announced today its first commercial shipment of its in-house developed Cannabis brand Mood Ring™ Hashish products.
These in-house developed Cannabis brand Mood Ring™ Hashish products will be distributed via the British Columbia Liquor Distribution Branch (BCLDB), the wholesaler and public retailer of non-medical cannabis throughout the province. This commercial shipment follows Neptune's December shipment of Mood Ring™ High CBD Oil and High CBD Capsules.
Mood Ring's THC dominant Legacy Hashish will soon be available for purchase through the BC Cannabis Store online, the 25 government-run retail locations, and will be available to the more than 300 private licensed retailers across British Columbia.
"This is a very exciting time for Neptune as we have now commenced production of Mood Ring™ hashish utilizing our newly implemented and proprietary solventless extraction for THC concentrates. We believe Mood Ring™ is well positioned to satisfy the significant consumer demand for affordable, sustainable, premium cannabis products ," said Michael Cammarata, President & Chief Executive Officer of Neptune Wellness Solutions Inc.
Neptune has also secured a supply agreement with the Ontario Cannabis Store (OCS), the wholesaler and sole online retailer for recreational cannabis in Ontario, for the sale and distribution of Mood Ring™. With that supply agreement in place, the Company has secured access to a footprint for Mood Ring™ totalling over 700 retail stores across British Columbia and Ontario, with the opportunity to scale to retailers in additional provinces upon securing supply agreements.
Neuraxpharm Group (Neuraxpharm), a leading European specialty pharmaceutical company focused on the central nervous system (CNS), today announced that its affiliate Neuraxpharm France has been selected as one of winners for the participation in a pilot program for the medical use of cannabis issued by The French National Agency for the Safety of Medicines and Health Products (ANSM), together with Panaxia Labs, Israel's largest medical cannabis manufacturer.
Neuraxpharm emerged as one of the first European pharmaceutical companies to include medical cannabis products in its portfolio, with a business collaboration starting last year for Germany, the largest cannabis market outside the USA. Now, as part of its strategic collaboration with Panaxia to enter the French market in the first phase, the companies submitted a joint application for the pilot program issued by ANSM. The program is based upon strict and demanding specifications in terms of compliance with good cultivation and manufacturing practices, the quality of the drugs and the safety of the distribution channel. France is the fifth largest pharmaceutical and CNS market in the world , and the country is known to have the strictest regulation in the Western world with regard to medical cannabis use. With a population of about 67 million, according to recent estimates there are about 700,000 patients in France who may be eligible for a prescription of a medical cannabis treatment.
Along with Neuraxpharm and Panaxia, three of the world's leading medical cannabis companies were selected as main suppliers for this pilot program, emphasizing Neuraxpharm's status as a leading player in the European medical cannabis market. As part of the program, four finished products were selected that have successfully met the stringent ANSM requirements in relation to finished products. They include the oral formulations in both the THC and CBD dominant forms together with the balanced THC / CBD formulations. The list of indications compiled by the ANSM includes diseases such as cancer, certain types of epilepsy, multiple sclerosis, palliative care and pain, where conventional treatments don't work.
This selection paves the way for supplying medical cannabis in state-of-the-art formulations to the patient, which will allow the effective start of the pilot program on March 31, 2021 at the latest. Monitoring of compliance and quality of the products supplied will continue throughout the pilot program.
The prestigious medical cannabis pilot program intends to provide free products to enrolled patients.
It will last two years and provide medical cannabis products to 3,000 patients who meet the determined criteria. Selected doctors, nurses and pharmacists participating in this program will undergo special training in registering and issuing medical cannabis prescriptions to patients. At the end, a decision will be made by the French Authorities regarding a license for the use and sale of medical cannabis products in France.
Dr. Jörg-Thomas Dierks, CEO of Neuraxpharm, commented: "We are excited to have been awarded and selected to participate in this pilot program for the medical cannabis use in France, a significant market in the fast-growing international medical cannabis sector. As one of the first pharmaceutical companies to distribute medical cannabis products in Europe, we are ideally positioned, in partnership with Panaxia, to responsibly introduce medical cannabis products to new markets, in line with our corporate mission to offer ground-breaking therapeutic CNS solutions to patients with unmet medical needs. We are confident that France will lead the way for other countries to embrace the use of medical cannabis in the coming years."
Investor ideas reminds all listeners to read our disclaimers and disclosures on the Investorideas.com website and that this podcast is not an endorsement to buy products or services or securities. Investors are reminded all investment involves risk and possible loss of investment.
Learn more about our cannabis podcasts at https://www.investorideas.com/Audio/Potcasts.asp
Investors can trade these stocks and other ideas on our site using our list of top stock trading apps including Robinhood , Acorn, Stash and others.
To hear more Investorideas.com podcasts visit: https://www.investorideas.com/Audio/.
Investorideas.com podcasts are also available on iTunes, Spotify, Google Play Music, Stitcher, Spreaker, YouTube via Spreaker, iHeartradio and Tunein.
Potcasts is now a certified word mark Trademark on the blockchain through Cognate, Inc. CM Certification-Registration Number: 10468217708
Follow us on Twitter https://twitter.com/Investorideas
Follow us on Facebook https://www.facebook.com/Investorideas
Follow us on YouTube https://www.youtube.com/c/Investorideas
Download our Mobile App for iPhone and Android
Join our Investor Club https://www.investorideas.com/membership/
800 665 0411